LG Chem-EuBiologics will locally manufacture vaccines
By Kim, Jin-Gu | translator Kang, Shin-Kook
24.04.26 05:45:35
가나다라
0
Signs agreement to contract manufacture undiluted solutions of acellular pertussis vaccines that had been fully dependent on imports
LG Chem will transfer the manufacturing process and testing method to EuBiologics …will further invest in EuBiologics facilities to meet GMP
▲Heuisul Park, Head of LG Chem’s Specialty Care Business Unit (left) and Yeong-Ok Baik, CEO of EuBiologics (right) are posing for a photo to commemorate the signing of a CMO agreement
LG Chem is joining hands with EuBiologics to speed up the development of pediatric combination vaccines that are being fully imported.
LG Chem announced today that it has signed an agreement with EuBiologics to outsource the production of 'acellular Pertussis (aP)', the main antigen used for its hexavalent combination vaccine 'LR20062.’
LR20062 is being developed as a vaccine to prevent 6 infectious diseases: diphtheria, tetanus, pertussis, polio, meningitis, and hepatitis B. Compared to the pentavalent (diphtheria-tetanus-pertussis-polio-meningitis) vaccine commonly used in Korea, the hexavalent vaccine can be administered twice less.
Under the agreement, LG Che
Kim, Jin-Gu(kjg@dailypharm.com)
If you want to see the full article, please JOIN US (click)